Dr. Lal PathLabs approved allotment of 5,000 Equity Shares under the ESOP 2010 Plan of the Company on 30th October 2024 through circular resolution.Powered by Capital Market - Live News

Net profit of Dr Lal Pathlabs rose 18.21% to Rs 129.20 crore in the quarter ended September 2024 as against Rs 109.30 crore during the previous quarter ended September 2023. Sales rose 9.80% to Rs 660.20 crore in the quarter ended September 2024 as against Rs 601.30 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales660.20601.30 10 OPM %30.6729.57 - PBDT218.40188.10 16 PBT183.10152.20 20 NP129.20109.30 18 Powered by Capital Market - Live News

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 23 October 2024, inter alia, have recommended the Second Interim dividend of Rs 6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live News

Dr Lal Pathlabs has allotted 93,900 equity shares under Dr. Lal PathLabs Employee Stock Option Plan, 2022.Pursuant to the above allotment, the paid-up equity share capital of the Company increased to Rs 83,57,42,520/- divided into 8,35,74,252 equity shares of Rs 10/- each.Powered by Capital Market - Live News